Builder looks to cold storage for steady work in a weak economy
Cold storage might become a hot business for a building contractor.
Eli Lilly and Co.
Articles
Part of Mississippi’s Zyprexa case against Lilly dismissed
Indianapolis-based Eli Lilly and Co. has won a bid to dismiss part of a negligence lawsuit brought by Mississippi that alleges
improper marketing of antipsychotic drug Zyprexa for unapproved uses.
Lilly extends research pact with India firm
Jubilant Organosys Ltd. and Indianapolis-based Eli Lilly and Co. extended their collaboration, which began in 2005, by five
years.
Lilly’s Cymbalta wins new approval for anxiety disorder
FDA action should boost sales of the Eli Lilly and Co. drug, which were already on pace to top $3 billion this year.
Lilly snags talent kudos
Fortune magazine ranked the drug company among the best in the world for managing talent.
Lilly stock droops after rival claims faster-acting impotence pill
California-based Vivus claims its drug acts in 30 minutes, compared with about 2 hours for Lilly’s Cialis.
Lilly to pay Utah $24 million to settle Zyprexa suit
Eli Lilly and Co. has agreed to pay Utah $24 million to settle a lawsuit claiming the company improperly marketed the antipsychotic
drug Zyprexa.
Lilly, WellPoint CEOs pin hopes on Senate
Drugmaker and health insurer bemoan aspects of House health reform bill and hope Senate crafts more industry-friendly bill.
Lilly reducing sales force by 191 as part of larger restructuring
Eli Lilly and Co. has notified the state that it plans to eliminate 191 sales jobs as part of a company-wide restructuring
announced
in September
that ultimately will result in 5,500 job cuts by the end of 2011.
Health care businesses at risk in House proposal
The health care overhaul bill produced by House Democrats would impose an array of new taxes, fees and government mandates
on major players in the health industry, including drug companies and big medical-device makers headquartered in Indiana.
Lilly opens new biotech center in San Diego
Lilly is opening the San Diego biotech center a year after launching a biotech R&D center in Indianapolis.
TechPoint to focus on IT firms specializing in medical, life sciences sectors
Long tracking the emergence of information technology firms involved in the health and life sciences sector, the state’s
IT trade group, TechPoint, is undergoing a mitosis of sorts to help fuel the trend. It has created Advancing
Life Science & Health Care Information Technology, or ALHIT, which will focus on growing this subset of the IT realm.
Lilly to move 1,000 from Faris campus
As it shrinks its work force, Indianapolis-based pharmaceutical firm Eli Lilly and Co. will move more than 1,000 employees to its corporate
center
by mid-2010.
Lilly settles Zyprexa case with S. Carolina for $45M
South Carolina Attorney General Henry McMaster said Friday that the state has reached a $45 million settlement with drug maker
Eli Lilly and Co. over the company’s marketing of an anti-psychotic drug.
Lilly needs to sell more Effient before Zyprexa loses patent protection
Sales of Eli Lilly and Co.’s newest drug were an afterthought during its Oct. 21 report on third-quarter earnings. The blood thinner Effient totaled up $22.6 million in sales—a mere 0.4 percent of Lilly’s total for
the quarter.
Eli Lilly CEO banking on new drug pipeline
CEO John Lechleiter says Lilly’s pipeline has helped it rebound from significant patent losses three times during his 30-year
career at the company. He’s betting there will be a fourth.
Lilly, GE announce cancer diagnostic breakthrough
Eli Lilly and Co. and General Electric Co. say they’ve made a breakthrough in cancer research that could help Lilly cut the size and cost of its clinical trials.
Uncertainty over drug pipeline sends Lilly shares down
For the first time publicly, Eli Lilly and Co. officials admitted the obvious: Their pipeline products
aren’t likely to offset the revenue the company will lose after its two bestsellers, Zyprexa and Cymbalta, lose patent exclusivity.
Lilly reports $942 million profit in third quarter
Excluding special items, Eli Lilly and Co.’s earnings per share spike 22 percent on the strength of Alimta, Cymbalta and Humalog
sales. Lilly’s revenue rose 7 percent in the quarter over the same period of 2008,
to $5.56 billion.
Medco plans to compare Plavix, Effient in study
Medco Health Solutions Inc. said Tuesday it will compare the blood thinner Plavix, the world’s second-best selling drug, with
Effient, a potential blockbuster drug sold by Indianapolis-based Eli Lilly and Co.